Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,006,346
  • Shares Outstanding, K 188,990
  • Annual Sales, $ 9,300 K
  • Annual Income, $ -643,200 K
  • EBIT $ -544 M
  • EBITDA $ -538 M
  • 60-Month Beta 1.08
  • Price/Sales 532.45
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 60.50% ( +5.86%)
  • Historical Volatility 66.01%
  • IV Percentile 27%
  • IV Rank 18.18%
  • IV High 151.63% on 11/18/24
  • IV Low 40.25% on 07/23/24
  • Put/Call Vol Ratio 0.04
  • Today's Volume 7,888
  • Volume Avg (30-Day) 5,816
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 179,373
  • Open Int (30-Day) 175,485

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.09
  • Number of Estimates 7
  • High Estimate -0.90
  • Low Estimate -1.30
  • Prior Year -0.96
  • Growth Rate Est. (year over year) -13.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.47 +17.89%
on 11/22/24
30.51 -13.18%
on 11/25/24
+3.45 (+14.97%)
since 11/20/24
3-Month
21.72 +21.96%
on 11/19/24
30.51 -13.18%
on 11/25/24
-0.25 (-0.93%)
since 09/20/24
52-Week
21.62 +22.53%
on 06/24/24
44.32 -40.23%
on 12/28/23
-11.71 (-30.65%)
since 12/20/23

Most Recent Stories

More News
BridgeBio Pharma, Inc. Announces Positive CHMP Recommendation for Acoramidis for ATTR-CM Treatment in Europe

CHMP recommends acoramidis for EU approval based on positive Phase 3 study results, with a final decision expected soon.Quiver AI SummaryThe Committee for Medicinal Products for Human Use (CHMP) has recommended...

BBIO : 26.49 (+1.07%)
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

BBIO : 26.49 (+1.07%)
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement Builds

Citi noted the positive clinical data and the competitive pricing of Attruby at $225,000 per year, below Pfizer’s tafamidis.

BBIO : 26.49 (+1.07%)
VTI : 293.28 (+1.14%)
XBI : 91.28 (+1.64%)
BridgeBio Pharma Announces FDA Approval of Attrubyâ„¢ to Treat ATTR-CM with Promising Cardiac Outcomes

BridgeBio's Attruby is FDA-approved for ATTR-CM, demonstrating significant cardiovascular benefits and providing lifetime free access for trial participants.Quiver AI SummaryBridgeBio Pharma, Inc. announced...

BBIO : 26.49 (+1.07%)
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

BBIO : 26.49 (+1.07%)
Insider Sale: Chief Executive Officer of $BBIO (BBIO) Sells 1,875 Shares

Neil Kumar, the Chief Executive Officer of $BBIO ($BBIO), sold 1,875 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.0% of...

BBIO : 26.49 (+1.07%)
Insider Sale: Secretary of $BBIO (BBIO) Sells 4,156 Shares

BRIAN C STEPHENSON, the Secretary of $BBIO ($BBIO), sold 4,156 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.2% of their...

BBIO : 26.49 (+1.07%)
BridgeBio Pharma Announces Positive 18-Month Results for Infigratinib in Achondroplasia from PROPEL 2 Study

Infigratinib shows significant growth improvements in children with achondroplasia, with ongoing trials and FDA breakthrough designations.Quiver AI SummaryBridgeBio Pharma announced positive results from...

BBIO : 26.49 (+1.07%)
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

BBIO : 26.49 (+1.07%)
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

BBIO : 26.49 (+1.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United...

See More

Key Turning Points

3rd Resistance Point 27.80
2nd Resistance Point 27.35
1st Resistance Point 26.92
Last Price 26.49
1st Support Level 26.04
2nd Support Level 25.59
3rd Support Level 25.16

See More

52-Week High 44.32
Fibonacci 61.8% 35.65
Fibonacci 50% 32.97
Fibonacci 38.2% 30.29
Last Price 26.49
52-Week Low 21.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar